• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于生成人淋巴因子激活的杀伤(LAK)细胞的高密度细胞培养系统,用于过继性免疫治疗的临床应用。

A high density cell culture system for generation of human lymphokine-activated killer (LAK) cells for clinical use in adoptive immunotherapy.

作者信息

Shimizu K, Park K, Yamada M, Tarura K, Matsui Y, Hayakawa T

机构信息

Department of Neurosurgery, Osaka University Medical School, Japan.

出版信息

J Clin Lab Immunol. 1990 May;32(1):41-7.

PMID:1967036
Abstract

A high density cell culture system has been developed for large-scale production of lymphokine-activated killer (LAK) cells from peripheral blood lymphocytes (PBLs) of malignant tumor patients. The system consists of a culture bag, which has two compartments separated by a semipermeable membrane, and an external rotator. The system allows for a long-term, at least 4 weeks, culture of LAK cells at high cell density in the inner compartment. The collected PBLs were first divided between the two culture bags and cultured without harvesting for 7-10 days to obtain LAK cells. Half of the LAK cells from each bag was administered to patients twice a week for clinical trials. Culture of the remaining half was continued following addition of a fresh culture medium. LAK cells were transferred to patients alternatively from each bag for the following 2-3 weeks. The total number of LAK cells administered amounted to 3.9-9.8 (mean 5.8) times more than the PBLs collected by leukapheresis (n = 10). The 5 x 10(6)/ml of PBLS of the initial concentration reached a maximum of 2 x 10(7)/ml. Our system does not need for a CO2 incubator. Cytotoxicity of the LAK cells was evaluated in 4 hr 51Cr release assays. Mean cytotoxicity at maximum cell density was 95.4 +/- 3.2% against ONS-12 (a human glioma cell) and 84.8 +/- 3.0% against Daudi cells (n = 10), but gradually decreased to about 50% at the end of fourth week of the culture period. Cell viability of the LAK cells was normally over 80% through the entire culture period.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

已开发出一种高密度细胞培养系统,用于从恶性肿瘤患者的外周血淋巴细胞(PBL)大规模生产淋巴因子激活的杀伤细胞(LAK细胞)。该系统由一个培养袋和一个外部旋转器组成,培养袋有两个由半透膜隔开的隔室。该系统允许在内隔室以高细胞密度长期培养LAK细胞,培养时间至少为4周。收集的PBL首先在两个培养袋之间分配,培养7 - 10天不收获以获得LAK细胞。每个袋中一半的LAK细胞每周给患者给药两次用于临床试验。添加新鲜培养基后继续培养剩余的一半。在接下来的2 - 3周内,从每个袋中交替将LAK细胞转移给患者。给药的LAK细胞总数比通过白细胞分离术收集的PBL多3.9 - 9.8倍(平均5.8倍)(n = 10)。初始浓度为5×10⁶/ml的PBL最高达到2×10⁷/ml。我们的系统不需要二氧化碳培养箱。通过4小时⁵¹Cr释放试验评估LAK细胞的细胞毒性。在最大细胞密度下,对ONS - 12(一种人胶质瘤细胞)的平均细胞毒性为95.4±3.2%,对Daudi细胞的平均细胞毒性为84.8±3.0%(n = 10),但在培养期第四周结束时逐渐降至约50%。在整个培养期内,LAK细胞的细胞活力通常超过80%。(摘要截断于250字)

相似文献

1
A high density cell culture system for generation of human lymphokine-activated killer (LAK) cells for clinical use in adoptive immunotherapy.一种用于生成人淋巴因子激活的杀伤(LAK)细胞的高密度细胞培养系统,用于过继性免疫治疗的临床应用。
J Clin Lab Immunol. 1990 May;32(1):41-7.
2
Lymphokine-activated killer cells: culture conditions for the generation of maximal in vitro cytotoxicity in cells from normal donors.
Cancer Res. 1987 Oct 15;47(20):5504-8.
3
Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.重组白细胞介素-2和淋巴因子激活的杀伤细胞过继性免疫疗法在人体中的实验室相关指标
Cancer Res. 1988 Aug 1;48(15):4409-16.
4
Lymphokine-activated killer cell expansion for clinical trials of adoptive immunotherapy with interleukin-2: optimization of the culture technique.
Mol Biother. 1990 Mar;2(1):32-7.
5
[Analysis of cytolytic activity and cell surface phenotypes of lymphokine activated killer cells stimulated with R-IL 2 and an anti-CD 3 antibody].[用重组白细胞介素-2(R-IL 2)和抗CD 3抗体刺激的淋巴因子激活的杀伤细胞的细胞溶解活性及细胞表面表型分析]
No To Shinkei. 1990 Jun;42(6):575-80.
6
[Induction of LAK cells by high density dialyzing culture device and its cytotoxicity].[高密度透析培养装置诱导LAK细胞及其细胞毒性]
Hum Cell. 1988 Mar;1(1):54-9.
7
[High yielding culture of LAK cells by the concentration rotary tissue culture system and its clinical application].[采用浓度旋转组织培养系统高产培养LAK细胞及其临床应用]
Nihon Gan Chiryo Gakkai Shi. 1989 Oct 20;24(10):2349-54.
8
Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.通过与低剂量白细胞介素-2加粒细胞-巨噬细胞集落刺激因子体外孵育,从外周血干细胞生成淋巴因子激活的杀伤(LAK)细胞。
Bone Marrow Transplant. 1997 Mar;19(6):545-51. doi: 10.1038/sj.bmt.1700698.
9
Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2.使用淋巴因子激活的杀伤细胞和白细胞介素2对大鼠神经胶质瘤进行过继性免疫治疗。
Cancer Res. 1990 Jul 15;50(14):4338-43.
10
Generation of human lymphokine-activated killer cells following an IL-2 pulse in elderly cancer patients.老年癌症患者经白细胞介素-2脉冲刺激后产生人淋巴因子激活的杀伤细胞。
Cytokine. 1998 Feb;10(2):132-9. doi: 10.1006/cyto.1997.0265.